Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans

Abstract

Background The messenger RNA (mRNA)–based vaccines BNT162b2 and mRNA-1273 are more than 90% effective against coronavirus disease 2019 (Covid-19). However, their comparative effectiveness for a range of outcomes across diverse populations is unknown. Methods We emulated a target trial using the electronic health records of U.S. veterans who received a first dose of the BNT162b2 or mRNA-1273 vaccine between January 4 and May 14, 2021, during a period marked by predominance of the SARS-CoV-2 B.1.1.7 (alpha) variant. We matched recipients of each vaccine in a 1:1 ratio according to their risk factors. Outcomes included documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, symptomatic Covid-19, hospitalization for Covid-19, admission to an intensive care unit (ICU) for Covid-19, and death from Covid-19. We estimated risks using the Kaplan–Meier estimator. To assess the influence of the B.1.617.2 (delta) variant, we emulated a second target trial that involved veterans vaccinated between July 1 and September 20, 2021. Results Each vaccine group included 219,842 persons. Over 24 weeks of follow-up in a period marked by alpha-variant predominance, the estimated risk of documented infection was 5.75 events per 1000 persons (95% confidence interval [CI], 5.39 to 6.23) in the BNT162b2 group and 4.52 events per 1000 persons (95% CI, 4.17 to 4.84) in the mRNA-1273 group. The excess number of events per 1000 persons for BNT162b2 as compared with mRNA-1273 was 1.23 (95% CI, 0.72 to 1.81) for documented infection, 0.44 (95% CI, 0.25 to 0.70) for symptomatic Covid-19, 0.55 (95% CI, 0.36 to 0.83) for hospitalization for Covid-19, 0.10 (95% CI, 0.00 to 0.26) for ICU admission for Covid-19, and 0.02 (95% CI, −0.06 to 0.12) for death from Covid-19. The corresponding excess risk (BNT162b2 vs. mRNA-1273) of documented infection over 12 weeks of follow-up in a period marked by delta-variant predominance was 6.54 events per 1000 persons (95% CI, −2.58 to 11.82). Conclusions The 24-week risk of Covid-19 outcomes was low after vaccination with mRNA-1273 or BNT162b2, although risks were lower with mRNA-1273 than with BNT162b2. This pattern was consistent across periods marked by alpha- and delta-variant predominance. (Funded by the Department of Veterans Affairs and others.)

Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes

“…25 26 This may be another contributing factor in observed differences in VE across products (i.e., higher VE for mRNA-1273 than BNT162b2) in other studies. 17 27 28…”

Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review

“…Such a strategy should be investigated for those who are likely to be low responders or at high risk of breakthrough infection. 55 A similar strategy could be used following booster vaccine doses upon evaluation of Ab kinetics. Alternatively, research should explore the use of age, sex, serostatus, and comorbidity to gauge the most suitable time to measure the antibody titer in order to assess the need for a booster dose based on the data presented in our report.…”

Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rdmRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults

“…Effectiveness against infection and severe disease has been reported to be higher for Spikevax compared to Comirnaty (28). In subjects vaccinated with two doses of a mRNA vaccine, Spikevax has been shown to induce two-fold antibody concentrations compared to Comirnaty (23).…”